Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
暂无分享,去创建一个
R. Bruno | S. Nielsen | B. Larance | L. Degenhardt | K. Lancaster | R. Ali | M. Shanahan | J. Grebely | M. Farrell | P. Dietze | S. Larney | Sonja Memedovic | Thomas Santo
[1] A. K. Burlew,,et al. Research on women with substance use disorders: Reviewing progress and developing a research and implementation roadmap. , 2019, Drug and alcohol dependence.
[2] B. Haight,et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial , 2019, The Lancet.
[3] R. Littlewood,et al. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine , 2018, Patient preference and adherence.
[4] J. Strang,et al. Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin. , 2018, Drug and alcohol dependence.
[5] M. Chen,et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial , 2018, JAMA internal medicine.
[6] T. Rhodes. The becoming of methadone in Kenya: How an intervention's implementation constitutes recovery potential. , 2018, Social science & medicine.
[7] R. Rosenthal,et al. Advances in the delivery of buprenorphine for opioid dependence , 2017, Drug design, development and therapy.
[8] A. Ritter,et al. Cost-effectiveness of center-based compulsory rehabilitation compared to community-based voluntary methadone maintenance treatment in Hai Phong City, Vietnam. , 2016, Drug and alcohol dependence.
[9] M. Chen,et al. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. , 2016, JAMA.
[10] B. Anderson,et al. Patients' Beliefs About Medications are Associated with Stated Preference for Methadone, Buprenorphine, Naltrexone, or no Medication-Assisted Therapy Following Inpatient Opioid Detoxification. , 2016, Journal of substance abuse treatment.
[11] J. Chalmers,et al. Trust, agency and control: Perspectives on methadone takeaway dosing in the context of the Victorian policy review. , 2015, Drug and alcohol review.
[12] B. Larance,et al. The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. , 2015, Drug and alcohol review.
[13] K. Mills,et al. Patterns and correlates of non-fatal heroin overdose at 11-year follow-up: findings from the Australian Treatment Outcome Study. , 2014, Drug and alcohol dependence.
[14] S. Walsh,et al. A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences From Around the World , 2014, Journal of addiction medicine.
[15] R. Mattick,et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. , 2014, Drug and alcohol dependence.
[16] J. Bell,et al. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing. , 2011, Drug and alcohol dependence.
[17] L. Degenhardt,et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. , 2011, Addiction.
[18] W. Hall,et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. , 2009, Drug and alcohol dependence.
[19] A. Winstock,et al. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. , 2008, Drug and alcohol review.
[20] John P. Allen,et al. The alcohol use disorders identification test: an update of research findings. , 2007, Alcoholism, clinical and experimental research.
[21] J. Rowe. A raw deal? Impact on the health of consumers relative to the cost of pharmacotherapy , 2007 .
[22] R P Mattick,et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.
[23] J. Penrod,et al. A Discussion of Chain Referral As a Method of Sampling Hard-to-Reach Populations , 2003, Journal of transcultural nursing : official journal of the Transcultural Nursing Society.
[24] R P Mattick,et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2009, The Cochrane database of systematic reviews.
[25] C. Holden. Counting the homeless. , 1986, Science.